Bank of America Cuts BioNTech (NASDAQ:BNTX) Price Target to $130.00

BioNTech (NASDAQ:BNTX) had its price objective lowered by Bank of America from $134.00 to $130.00 in a research note published on Wednesday,MarketScreener reports. Bank of America currently has a buy rating on the stock.

Several other research firms have also weighed in on BNTX. Morgan Stanley cut their target price on BioNTech from $133.00 to $131.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. JPMorgan Chase & Co. raised their price target on BioNTech from $116.00 to $121.00 and gave the company a “neutral” rating in a research report on Monday, September 22nd. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an “overweight” rating in a research report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research report on Tuesday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $136.00 price target on shares of BioNTech in a research report on Monday, September 8th. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.96.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $105.66 on Wednesday. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $81.20 and a 1 year high of $129.27. The business has a fifty day simple moving average of $103.20 and a 200 day simple moving average of $104.46. The firm has a market cap of $25.40 billion, a price-to-earnings ratio of -66.04 and a beta of 1.45.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The firm had revenue of $306.46 million for the quarter, compared to analysts’ expectations of $161.26 million. During the same quarter in the prior year, the business posted ($3.36) earnings per share. BioNTech’s revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in BNTX. Banque Cantonale Vaudoise acquired a new stake in BioNTech during the first quarter valued at approximately $36,000. Financial Consulate Inc. acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $36,000. LRI Investments LLC boosted its holdings in shares of BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after acquiring an additional 312 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in shares of BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after acquiring an additional 472 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.